LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`if the phrase "IF REQUIRED, FOREIGN FILING
`The applicant has been granted a license under 35 U.S.C. 184,
`LICENSE GRANTED"followed by a date appears on this form. Such licenses are issuedin all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope andlimitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicatedis the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This licenseis to be retained by the licensee and maybe usedat any time onor after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grantof a license doesnot in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Governmentcontract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselvesof current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOESNOTappear on this form. Applicant maystill petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from thefiling date of the application. If 6 months has lapsed
`from thefiling date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee mayforeign file the application pursuant to 37 CFR 5.15(b).
`
`
`SelectUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`businessinvestment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote andfacilitate business investment. SelectUSAprovides information assistance to the international investor
`community; serves as an ombudsmanfor existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic developmentorganizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http:/Awww.SelectUSA.govor call
`+1-202-482-6800.
`
`page 3 of 3
`
`TEVA - EXHIBIT 1004 (PART 3 OF 5)
`
`0411
`
`0411
`
`TEVA - EXHIBIT 1004 (PART 3 OF 5)
`
`

`

`Electronic AcknowledgementReceipt
`
`18616805
`
`14222478
`
`Application Number:
`
`International Application Number:
`
`Confirmation Number:
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`Utility under 35 USC 111)
`
`First Named Inventor/Applicant Name:
`
`Andrew Acheampong
`
`Customer Number:
`
`51957
`
`Laura Lee Wine/Ken Dinh
`
`Filer Authorized By:
`
`Laura Lee Wine
`
`Attorney Docket Number:
`
`17618CON6CON1 (AP)
`
`Receipt Date:
`
`28-MAR-2014
`
`Filing Date:
`
`Time Stamp:
`
`16:55:06
`
`Application Type:
`
`Paymentinformation:
`
`Submitted with Payment
`
`File Listing:
`
`Pages
`Multi
`File Size(Bytes)/
`DocumentDescription
`Document
`
`
`
`Number Message Digest|Part/.zip|P (if appl.)
`4262912
`
`Information:
`
`Non Patent Literature
`
`PedersenExpertOpin1415_143
`6_2001.pdf
`
`Offbacdd587d316724d2c00a7e64fcdbcbed|
`49e4
`
`0412
`
`0412
`
`

`

`:
`ons
`Phillips_CyclosporineJOCP1_20
`00.pd¢
`
`
`
`Non Patent Literature
`
`Sall_2000.pdf
`
`208829
`
`065c1861383 1a6d2cf5a88066e/0ae03daa
`e1b29
`
`Non Patent Literature
`
`SandbornGastroenterology142
`9.1435_1994.pd¢
`
`872000
`
`730e8bcd0c58076ab6f0163f4551 eff0fs07e}
`5c6
`
`Non Patent Literature
`
`Sandborn_1993.pdf
`
`1969241
`
`10802861668ec206f085b7aa854a3b76526
`
`OZ
`
`Non Patent Literature
`
`Non Patent Literature
`
`Present_1993.pdf
`
`1385594
`
`63acdf4c243d41621f7001e9c76dbf167d4e}
`id
`
`1624134
`
`baefc9d58e2e27ac5b6a99bd9151 eb6a4Te
`80d81
`
`Non Patent Literature
`
`.
`.
`Restasis_Increasing_tear_Prod
`uction_2009.pdf
`
`332259
`
`0a1285bcf642f927562ba180ba3ba5446eb
`2afed
`
`Non Patent Literature
`
`RestasisProductInfoSheets.pdf
`
`844b6588f9ea989c6c37ffe4c0b220c95Offal
`dea
`
`Non Patent Literature
`
`;
`;
`;
`Robinsonaustraliandentaljourn
`al206_211_2003.pdf
`
`768117
`
`798558b0fd44a086f/1 fe1076b47333898b
`e976
`
`Non Patent Literature
`
`;
`;
`RudingerPeptideHormones1_7
`_1976.pdf
`
`2488192
`
`b6fcl 8b6ad98c34de41f2d461a1f5736500b
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`0413
`
`

`

`2
`
`SchwabPharmacokinet723_751
`~2001.pdf
`
`Non Patent Literature
`
`TesavibulTopicalCyclosporine1
`996.pdf
`
`fcAbba0a0ffd0194e2146e1e1dbb52551410
`edeb
`
`Non Patent Literature
`
`Medical_Dictionary_2005.pdf
`
`670357
`
`2816eb8d 1deb894d8911 bacd 15ed728364}
`42681
`
`O41
`
`Non Patent Literature
`
`Non Patent Literature
`
`Secchi_1990.pdf
`
`Non Patent Literature
`
`Small_1999.pdf
`
`4260474
`
`decfedf8ccd3394e49e7e8a02f40d1 3d5023
`683f
`
`3200224
`
`8a65624bb284fb7ad8fcAcc8ba5ee1a92ffe
`4b94
`
`166579
`
`a6352b5 109a02b19264b6b81 164b62<481
`68e92f
`
`Non Patent Literature
`
`Small_2002.pdf
`
`777a603fb0b1 9562a66c525571b8108210¢
`829a2
`
`Non Patent Literature
`
`Smilek_1991.pdf
`
`1645292
`
`a604ec7f03b90bf8fd3c8882dedce3c7b3fc
`802d
`
`Non Patent Literature
`
`Stephenson_The_latest_uses_
`of_Restasis.pdf
`
`2875746
`
`c5d5cdd66d2f333c39c173e5e665d5bacd0)
`Qedad
`
`Non Patent Literature
`
`Stevenson_2000.pdf
`
`255058
`
`2£70a01929808bc46f5e822eb9cfcc28fcea7|
`ab4
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`0414
`
`

`

`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Non Patent Literature
`
`USP-1990.pdf
`
`Non PatentLiterature
`
`Non Patent Literature
`
`Tsubota_1998.pdf
`
`Non Patent Literature
`
`Van_der_Reijden_1999.pdf
`
`Non Patent Literature
`
`Wiederholt-1986.pdf
`
`Non Patent Literature
`
`Winter_1993.pdf
`
`Non Patent Literature
`
`13961828.pdf
`
`Non Patent Literature
`
`90009944.pdf
`
`.
`.
`.
`Tibell_Cyclosporin_A_in_Fat_E
`mulsion_115_121_76.pdf
`
`03dc9
`
`2071579
`
`03560775cf2863fb6a6247cb268f5de039
`Ob60
`
`697241
`
`5c1942bd49b4119100efa0409c42cda5c/1
`82d19
`
`2353818
`
`£0929e8a59cf1006529e4db58b285eec963
`b5c0e
`
`2709253
`
`daff1e358e3501 bdaae2d9ea3dbc422c6cd
`dalaf
`
`1534440
`
`7a1f27312cc464030a5d8f700cd70c3be91 q
`fad1
`
`1231303
`
`441701043d7f2a34aab980c3e2a2b0db53e
`b3d7f
`
`2596695
`
`660e95b406b8f6ac91 600605af4712d74c8q
`77bb
`
`1904560
`
`4b5aa1ab68a1940d5930d4265e9053cf672|
`
`0415
`
`0415
`
`

`

`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish thefiling date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903indicating acceptanceof the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`This AcknowledgementReceipt evidences receipt on the noted date by the USPTOofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`the application.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`0416
`
`0416
`
`

`

`Doc code: IDS
`
`Doc description: Information Disclosure Statement (IDS) Filed
`
`Application Number
`
`14222478
`
`Me TENT SYeeOe|Fist Named vente
` Notforsubmiscionunderarernagy
`[Atul
`( Not for submission under 37 CFR 1.99)
`
`Examiner Cite
`Initial
`No
`
`Patent Number
`
`Kind
`Code!
`
`Issue Date
`
`Nameof Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`3278447
`
`1966-10-11
`
`Thomas McNicholas
`
`4388229
`
`1983-06-14
`
`Cherng-Chyi Fu
`
`4388307
`
`1983-06-14
`
`Thomas Cavanak
`
`Delevallee etal
`
`4649047
`
`4764503
`
`4839342 aa
`
`Sk
`fe
`co4614736
`fe
`Sf
`aa
`fe
`
`4814323
`
`0417
`
`0417
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`1990-11-13
`
`David Horrobin
`
`:
`
`Nussenblatt et al Pie
`
`-
`a -
`aee
`Sie
`-
`Sie
`-
`
`11
`
`4996193
`
`5011681
`
`5047396
`
`:
`
`:
`
`a -
`
`0418
`
`

`

`w oO a
`
`ie
`oe
`pefee
`
`pe|feeoP
`rm
`pm|
`k
`Se
`
`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`N oO
`
`No =
`
`aS
`
`NNh
`
`Anthony Dziabo
`
`=“
`
`Chartrain et al
`
`vstn
`
`0419
`
`----:
`
`aaS
`
`aS
`
`ka
`
`No ©
`
`N co
`
`0419
`
`

`

`XS a
`
`aaaaa a
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
` [Fi:<t Named inventor
`
`Attorney Docket Number
`
`ow
`
`aNh
`
`ow ww
`
`1997-01-07
`
`Shahar et al
`
`1997-03-25
`
`Walchet al
`
`5639724 7 -
`
`1997-06-17
`
`Thomas Cavanak
`
`5652212
`
`1997-07-29
`
`Cavanak et al
`
`5719123
`
`5721273
`
`ow oO
`
`th oO
`
`5739105
`
`5753166
`
`0420
`
`

`

`pom|
`pm|
`om|
`emf
`coef
`orf
`
`oaNh pofe
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`.
`pNoTOr suOmESsion nee
`
`Ant
`
`Uni
`
`rt Unit
`
`ANDREW ACHEAMPONG
`
`ANDREWACHEAMPONG
`
`1621
`
`Examiner Name
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`iNo
`
`1998-06-16
`
`Choetal
`
`Soe
`
`B oo
`
`‘KR
`
`aS
`
`ie
`
`0421
`
`1998-08-25
`
`Bernard Sherman
`
`1998-09-15
`
`Elias et al
`
`Yoshitaka Yamamura
`
`Bernard Sherman
`
`/////
`
`aS
`
`eaaS
`
`eaS
`
`ol =
`
`ie
`
`o1 oO
`
`0421
`
`

`

`Friedman etal
`
`epe
`Se
`Sie
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`Kawashimaet al
`
`Thomas Cavanak
`
`Bernard Sherman
`
`vsa
`
`aS
`
`oe
`Sie
`Sie
`
`ap
`
`aS
`
`ie
`oe
`
`
`
`INFORMATION DISCLOSU
`STATEMENTBY APPLICA
`ii
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`14222478
`
`Filing Date
`
`2014-03-21
`
`Art Unit
`
`rr First Named Inventor|ANDREWACHEAMPONG
`
`0422
`
`

`

`Choetal a
`
`a a
`
`ap
`
`o
`oe
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
` [Fi:<t Named inventor
`
`Attorney Docket Number
`
`pe
`
`_—
`
`2000-12-12
`
`Bernard Sherman
`
`2001-03-06
`
`Bernard Sherman
`
`2001-07-03
`
`Michael Garst
`
`2001-07-03
`
`ap
`
`oe
`
`0423
`
`

`

` [Fi:<t Named inventor
`
`Attorney Docket Number
`
`~“ oi
`
`2001-07-31
`
`Chen etal
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ooco|~Ro=oOco
`
`2001-10-23
`
`Thomas Cavanak
`
`~oO
`
`~ ~
`
`lo)lee)&aw
`
`©o o
`
`0424
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
` [Fi:<t Named inventor
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`a -
`
` a -
`
`aoe
`a -
`a -
`pe
`-
`Sie
`-
`
`Yoichi Kawashima
`
`vt
`
`0425
`
`0425
`
`

`

`Sie
`
`ie
`Sie
`8288348 7 2012-10-16
`fem
`Sie
`Sle
`Sie
`
`2014-01-14|Acheamponget al U.S. Application No. 13/967,163 and
`
`8629111
`its entire prosecution history
`
`8633162
`
`2014-01-21
`
`Acheampongetal
`
`U.S. Application No. 13/967,179 and
`its entire prosecution history
`
`
`
`8642556 2014-02-04_|Acheamponget al U.S. Application No. 13/967,189 and
`
`its entire prosecution history
`
`8648048
`
`2014-02-11
`
`Acheampongetal
`
`U.S. Application No. 13/967,168 and
`its entire prosecution history
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`0426
`
`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`2007-10-30
`
`Changetal
`
`U.S. Application No. 11/255,821 and
`its entire prosecution history
`
`2007-11-20
`
`James Chang
`
`U.S. Application No. 11/181,178 and
`its entire prosecution history
`
`7501393
`
`2009-03-10
`
`Tien etal
`
`U.S. Application No. 11/161,218 and
`its entire prosecution history
`
`8211855
`
`2012-07-03
`
`Changetal
`
`Changetal
`
`U.S. Application No. 11/857,223 and
`its entire prosecution history
`
`U.S. Application No. 11/917,448 and
`its entire prosecution history
`
`2013-12-31
`
`Acheampongetal
`
`U.S. Application No. 11/897,177 and
`its entire prosecution history
`
`Se
`
`aaS
`
`0426
`
`

`

`Examiner
`Initial*
`
`Publication
`Number
`
`Publication
`e1| Date
`
`Cod
`
`Nameof Patentee or Applicant Pages,Columns,Lines where
`of cited Document
`Relevant Passagesor Relevant
`Figures Appear
`
`20010003589
`
`20010014665
`
`20010036449
`
`20020012680
`
`20020013272 72002-01-31
`
`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`Petszulat etal
`
`2002-02-07
`
`Floc'h et al
`
`2002-02-07
`
`Richter et al
`
`2002-02-28
`
`Olbrich etal
`
`2002-04-18
`
`Yoichi Kawashima
`
`2002-08-08
`
`_____
`
`20020016290
`
`20020016292
`
`20020025927
`
`20020045601
`
`20020107183
`
`0427
`
`

`

`20030109425 feame
`
`a a
`
`20030087813
`
`feamms
`aa
`
`20030104992
`
`N oO
`
`20030108626
`
`No =
`
`0428
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
` [Fi:<t Named inventor
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`= =
`
`20020119190
`
`— No
`
`20020165134
`
`20030021816
`
`20030044452
`
`= ol
`
`20030055028
`
`2003-03-20
`
`Stergiopoulosetal
`
`a
`
`20030059470
`
`= ~I
`
`20030060402
`
`_ ——
`
`0428
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`NNh
`
`20030109426
`
`—
`
`N ow
`
`20030133984
`
`2003-07-17
`
`Ambuhl et al
`
`20030143250
`
`——
`
`prowAeeanpong—_—(US,AltonNo1027a0429
`20070149447 pfamie
`
`aa
`eee
`
`ae
`
`20030147954
`
`NOo)
`
`20030166517
`
`Sfame
`
`20050014691
`
`N co
`
`20050059583
`
`20070015691
`
`20070027072
`
`w =
`
`20070087962
`
`aNh
`
`0429
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`20130059796
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`
`FOREIGN PATENT DOCUMENTS
`
`0430
`
`20080039378
`
`2008-02-14
`
`Graham etal
`
`U.S. Application No. 11/781,095 and
`its entire prosecution history**
`
`20080070834
`
`2008-03-20
`
`Changetal
`
`U.S. Application No. 11/940,652 and
`its entire prosecution history
`
`20080146497
`
`2008-06-19
`
`Graham et al
`
`U.S. Application No. 11/858,200 and
`its entire prosecution history
`
`20080207495
`
`2008-08-28
`
`Graham et al
`
`U.S. Application No. 12/035,698 and
`its entire prosecution history
`
`20090131307
`
`2009-05-21
`
`Tien etal
`
`U.S. Application No. 12/361,335 and
`its entire prosecution history
`
`20100279951
`
`2010-11-04
`
`Morganet al
`
`U.S. Application No. 121771,952 and
`its entire prosecution history
`
`20110009339
`
`2011-01-13
`
`Rhett Schiffman
`
`U.S. Application No. 12/759,431 and
`its entire prosecution history**
`
`20110294744
`
`2011-12-01
`
`Morganet al
`
`U.S. Application No. 19/115,764 and
`its entire prosecution history
`
`20120270805
`
`2012-10-25
`
`Changetal
`
`U.S. Application No. 13/536,479 and
`its entire prosecution history
`
`2013-03-07
`
`Changetal
`
`U.S. Application No. 19/649,287 and
`its entire prosecution history
`
`0430
`
`

`

`INFORMATION DISCLOSURE First Named Inventor|ANDREW ACHEAMPONG
`
`STATEMENT BY APPLICANT |,
`-
`oe
`rt Unit
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`
`TBD
`
`1621
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`Examiner] Cite|Foreign Document Country Publication where Relevant
`
`Pages, Columns, Lines
`Nameof Patentee or
`
`
`
`Initial*
`Number?
`Date
`Applicantof cited
`Passages or Relevant
`No
`Document
`Figures Appear
`
`1
`
`19810655
`
`DE
`
`1999-09-16
`
`Eberhard-Karis-
`
`Universitat Tubingen
`Universitatskl
`
`0448856e|1991-10-02 ChatfieldPharmaceutical
`
`ABBOTT
`
`0480690e|1992-04-15 IOLABCORPORATION
`
`2001-04167 1 1993-01-07
`
`
`— eo]—
`
`_ eo] |
`_— eo] |
`ped
`ped
`ped
`pd
`
`)
`
`D
`a
`a
`
`LLT Institute Co., Ltd.
`
`Cipla Limited
`
`Allergan, Inc.
`
`Won Jin BiopharmaCo.,
`Ltd
`
`Cipla Limited
`
`Transneuronix, Inc.
`
`0431
`
`0431
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Filing Date
`
`2014-03-21
`ANDREW ACHEAMPONG
`on
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`2002-02-07
`
`Pharmasol GMBH
`
`2002-06-27
`
`LG Household & Health
`Care Ltd.
`
`fem|
`fele|
`|ffm|
`Pe
`ed
`
`Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111
`
`2003-04-17
`
`Enanta Pharmaceuticals,
`Inc.
`
`Yissum Research
`
`2003-053405
`
`2003-07-03
`
`Development Company o
`the Hebrew
`
`If you wish to add additional Foreign Patent Documentcitation information please click the Add button
`
`NON-PATENT LITERATURE DOCUMENTS
`
`,
`,
`Examiner] Cite
`ee
`Initials
`No
`
`Include nameof the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`;
`publisher, city and/or country where published.
`
`ABDULRAZIK, M. ET AL, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emulsion's Surface Charge on
`Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6)
`
`ACHEAMPONG, ANDREW ETAL, Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes, 1996, 179
`
`ACHEAMPONG, ANDREW ETAL, Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, Adv. Exp. Med. Biol.,
`1998, 1001-1004, 438
`
`ACHEAMPONG, ANDREW ETAL, Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to
`Albino Rabbits and Beagle Dogs, Current Eye Research, 1999, 91-103, 18(2)
`
`AKPEK, ESEN KARAMURSEL ETAL, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant
`
`0432
`
`0432
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`ANGELOV,O. ET AL, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp MedBiol, 1998,
`991-995, 438
`
`ANGELOV, O. ET AL, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, XIth Congress
`of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU
`
`ARDIZZONE, SANDRO ETAL, A Practical Guide to the Management of Distal Ulcerative Colitis, Drugs, 1998,
`519-542, 55(4)
`
`BANIC, MARKO ETAL, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestive Diseases and
`Sciences, June 2002, 1362-1368, 47(6)
`
`BF GOODRICH, CARBOPOL 1342 A New Polymer Which Functions Both As a Thickener And An Emulsifier TDS-73,
`Carbopol High Performance Polymers, 1987, 25 Pages
`
`October 1995, 1154-1159, 84(10)
`
`BREWSTER, MARCUS ETAL, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-R-cyclodextrin-
`Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,
`Journal of Pharmaceutical Sciences, March 1997, 335-339, 86(3)
`
`BF GOODRICH, Carbopol, Pemulen and Noveon Polymers, 1995, 2 Pages
`
`BF GOODRICH, Pemulen Polymeric Emulsifiers TDS-182, March 1993, 9 Pages
`
`BONINI, S. ET AL, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18
`
`BREWSTER, MARCUS ETAL, Enhanced Delivery of Ganciclovir to the Brain Through the Use of Redox Targeting,
`Antimicrobial Agents and Chemotherapy, Apr 1994, 817-823, 38(4)
`
`BREWSTER, MARCUS ETAL, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-f-
`cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences,
`
`0433
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`NNNh>=owNh=>
`
`DONNENFELD, ERIC D., The Economics Of Using Restasis, Ophthalmology Management, 10/2003, 3 pages, US
`
`DROSOS, A. A. ET AL, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh.,
`1998, 77-80, 60(4)
`
`DROSOS, A.A. ET AL, Cyclosporin A Therapy in Patients with Primary Sjogren's Syndrome: Results at One Year,
`Scand J Rheumatology, 1986, 246-249, 61
`
`DURRANI, A.M. ET AL, Pilocarpine Bioavailability From a Mucoadhesive Liposomal Ophthalmic Drug Delivery
`System, International Journal of Pharmaceutics, 1992, 409-415, 88
`
`EISEN, DRORE ETAL, Topical Cyclosporine for Oral Mucosal Disorders, J Am Acad Dermatol, Dec. 1990,
`1259-1264, 23
`
`EPSTEIN, JOEL ET AL, Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Muscosal Reactions,
`Oral Surg Oral Med Oral Pathol Oral, 1996, 532-536, 82
`
`BRINKMEIER, THOMASETAL, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with
`Response to Cyclosporine and Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81
`
`CASTILLO, JOSE M. BENITEZ DEL ETAL, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium
`Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91
`
`CHEEKS, LISA ETAL, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration
`Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7)
`
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages
`
`DING, SHULIN ET AL, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm
`Res, 1997, 1 page, 14 (11)
`
`~I
`
`co
`
`= oO
`
`N oO
`
`NoB
`
`N ai
`
`NOo)
`
`Nh ~
`
`0434
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`w Co
`
`HUNTER, P.A. ET AL, Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection, Clin Exp
`Immunol, 1981, 173-177, 45
`
`JUMAA, MUHANNADETAL, Physicochemical Properties and Hemolytic Effect of Different Lipid Emulsion
`Formulations Using a Mixture of Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73
`
`KANAI, A. ET AL, The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Eye Drops, Transplantation Proceedings,
`February 1989, 3150-3152, Vol. 21
`
`KANPOLAT, AYFER ETAL, Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical
`Drop and Collagen Shield Administration, Cornea/External Disease, April 1994, 119-122, 20(2)
`
`ERDMANN, S. ET AL, Pemphigus Vulgaris Der Mund- Und Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral
`Mucosaand the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286, 72(4)
`
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye (6/18/1999). Accessed online at http:/Avww.
`dryeyeinfo.org/Restasis_Cyclosporine.htm on 8/14/09. 1 Page
`
`GAETA, G.M. ET AL, Cyclosporin Bioadhesive Gel in the Topical Treatment of Erosive Oral Lichen Planus,
`International Journal of Immunopathology and Pharmacology, 1994, 125-132, 7(2)
`
`GIPSON, ILENE ET AL, Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease, The Ocular
`Surface, April 2004, 131-148, 2(2)
`
`GREMSE, DAVID ET AL, Ulcerative Colitis in Children, Pediatr Drugs, 2002, 807-815, 4(12)
`
`GUNDUZ, KAAN ETAL, Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's
`Syndrome, Acta Ophthalmologica, 1994, 438-442, 72
`
`http:/Aweb.archive.org/web/2001030625323/http://www.surfactant.co.kr/surfactants/pegester.html, 2001, 6 Pages,
`retrieved on 7/05/2008
`
`N co
`
`No ©
`
`w oO
`
`w =
`
`wowww
`
`w o
`
`owOo
`
`ow “J
`
`0435
`
`

`

`KAUR, RABINDER ETAL, Solid Dispersions of Drugs in Polyocyethylene 40 Stearate: Dissolution Rates and Physico-
`Chemical Interactions, Journal of Pharmacy and Pharmacology, December 1979, 48P
`
`KUWANO, MITSUAKI ET AL, Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits, Pharmaceutical
`Research, January 2002, 108-111, 19(1)
`
`Lambert Technologies Corp. Material Safety Data Sheet for LUMULSE ™ POE-40 MS KP, last revision 8/22/2003. 3
`pages
`
`LEIBOVITZ, Z. ET AL., Our Experience In Processing Maize (Corn) Germ Oil, Journal Of The American Oil Chemists
`Society, 02/1983, 395-399, 80 (2), US
`
`LIXIN, XIE ET AL, Effect Of Cyclosporine A Delivery System in Corneal Transplantation, Chinese Medical Journal,
`2002, 110-113, 115 (1), US
`
`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`Restasis ® Product Information Sheet, Allergan, Inc., 2009, 5 Pages
`
`ow oO
`
`th oO
`
`XS —
`
`iNo
`
`&&&ol&w
`
`XoO
`
`Bh XQ
`
`th oo
`
`tS oO
`
`LOPATIN, D.E., Chemical Compositions and Functions of Saliva, 8/24/2001, 31 Pages
`
`LYONS, R.T. ET AL, Influence of Three Emulsion Formulation Parameters on the Ocular Bioavailability of
`Cyclosporine A in Albino Rabbits, Am Assoc Pharm Sci, 2000, 1 Page, 2(4)
`
`PEDERSEN, ANNE MARIE ETAL, Primary Sjogren's Syndrome: Oral Aspects on Pathogenesis, Diagnostic Criteria,
`Clinical Features and Approaches for Therapy, Expert Opin Pharma, 2001, 1415-1436, 2(9)
`
`PHILLIPS, THOMASETAL, Cyclosporine Has a Direct Effect on the Differentiation of a Mucin-Secreting Cell Line,
`Journal of Cellular Physiology, 2000, 400-408, 184
`
`PRESENT, D.H. ET AL, Cyclosporine and Other Immunosuppressive Agents: Current and Future Role in the
`Treatment of Inflammatory Bowel Disease, American Journal of Gastroenterology, 1993, 627-630, 88(5)
`
`0436
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`Restasis® Increasing Tear Production, Retrieved on 08/14/2009, http://www.restasisprofessional.com/_clinical/
`clinical_increasing.htm 3 pages
`
`ROBINSON, N.A. ET AL, Desquamative Gingivitis: A Sign of Mucocutaneous Disorders - a Review, Australian Dental
`Journal, 2003, 205-211, 48(4)
`
`RUDINGER, J., Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence, Peptide
`Hormones, 1976, 1-7
`
`9633-9637, 88
`
`SMALL, DAVID ET AL, Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A
`ophthalmic Emulsions in Patients with Moderate to Severe Dry Eye Disease, Journal of Ocular Pharmacology and
`Therapeutics, 2002, 411-418, 18(5)
`
`SALL, KENNETH ETAL, Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic
`Emulsion in Moderate to Severe Dry Eye Disease, Ophthalmology, 2000, 631-639, 107
`
`SANDBORN, WILLIAM ETAL, A Placebo-Controlled Trial of Cyclosporine Enemasfor Mildly to Moderately Active
`Left-Sided Ulcerative Colitis, Gastroenterology, 1994, 1429-1435, 106
`
`SANDBORN, WILLIAM ET AL, Cyclosporine Enemas for Treatment-Resistant, Mildly to Moderately Active, Left-Sided
`Ulcerative Colitis, American Journal of Gastroenterology, 1993, 640-645, 88(5)
`
`SCHWAB, MATTHIAS ET AL, Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease, Clin
`Pharm, 2001, 723-751, 60(10)
`
`SECCHI, ANTONIO ETAL, Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis, American
`Journal of Ophthalmology, December 1990, 641-645, 110
`
`SMALL, DAVE ET AL, The Ocular Pharmacokinetics of Cyclosporine in Albino Rabbits and Beagle Dogs, Ocular Drug
`Delivery and Metabolism, 1999, 54
`
`SMILEK, DAWNETAL, A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to
`Prevent Rather Than Induce Experimental Autoimmune Encephalomyelitis, Proc. Natl. Acad. Sci., Nov 1991,
`
`0437
`
`

`

`STEPHENSON, MICHELLE, The Latest Uses Of Restasis, Review Of Ophthalmology, 12/30/2005, 7 Pages, US
`
`STEVENSON, DARAETAL, Efficacy and Safety of Cyclosporin A ophthalmic Emulsion in the Treatment of Moderate-
`to-Severe Dry Eye Disease, Ophthalmology, 2000, 967-974, 107
`
`TESAVIBUL, N. ET AL, Topical Cyclosporine A (CsA) for Ocular Surface Abnormalities in Graft Versus Host Disease
`Patients, Invest Ophthalmol Vis Sci, Feb 1996, $1026, 37(3)
`
`The Online Medical Dictionary, Derivative, Analog, Analogue, Xerostomia, accessed 7/7/2005 and 7/13/2005, 6 Pages
`
`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`U.S. Pending Application: 13/961,828 and its entire prosecution history, Filed on August 07, 2013
`
`The United States Pharmacopeia, USP XXII, January 1990, 8 Pages, 22
`
`TIBELL, A. ET AL., Cyclosporin A In Fat Emulsion Carriers: Experimental Studies On Pharmacokinetics And Tissue
`Distribution, Pharmacology & Toxicology, 1995, 115-121, 76, US
`
`TSUBOTA, KAZUO ETAL, Use of Topical Cyclosporin A in a Primary Sjogren's Syndrome Mouse Model, Invest
`Ophthalmol Vis Sci, Aug. 1998, 1551-1559, 39(9)
`
`VAN DER REIJDEN, WILLY ET AL, Treatment of Oral Dryness Related Complaints (Xerostomia) in Sjogren's
`Syndrome, Ann Rheum Dis, 1999, 465-473, 58
`
`WIEDERHOLT, MICHAEL ET AL, Pharmacokinetic of Topical Cyclosporin A in the Rabbit Eye, Invest Ophthalmol Vis
`Sci, 1986, 519-524, 27
`
`WINTER, T.A. ET AL, Cyclosporin A Retention Enemasin Refractory Distal Ulcerative Colitis and 'Pouchitis', Scand J
`Gastroenterol, 1993, 701-704, 28
`
`0438
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`U.S. Re-Examination Application: 90/009,944 and its entire prosecution history, Filed on August 27, 2011
`
`if English languagetranslation is attached.
`
`? Enter office that issued the document, by the two-letter code (WIPO
`or MPEP 901.04.
`1 See Kind Codes of USPTO Patent Documents at
`Standard ST.3).
`3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
`5 Applicant is to place a check mark here
`
`If you wish to add additional non-patentliterature document citation information please click the Add button
`
`EXAMINER SIGNATURE
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`0439
`
`0439
`
`

`

`SRA, oeeee [fistNamed inventor
`“Notforzubmissionunderar creae)
`[ATU
`( Not for submission under 37 CFR 1.99)
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`[-]
`
`That each item of information contained in the information disclosure statement wasfirst cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`VA 22313-1450.
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was Known to
`any individual designated in 37 CFR 1.56(c) more than three monthsprior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`**Signature indicates consideration of publication andfile history. The Examiner has access to these materials through the PTO computer
`systems. If additional copies are desired, please notify the Applicants through their attorneys.
`
`L]
`
`[_] See attached certification statement.
`[_] Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`DX] None
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Name/Print
`
`Registration Number
`
`68,681
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public whichis to file (and by the USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending uponthe individual case. Any comments on the amount of time you
`require to complete this form and/o